Vanda Pharmaceuticals reported $1.85M in Stock for its fiscal quarter ending in December of 2025.





Stock Change Date
Acadia Pharmaceuticals USD 40.36M 68.31M Sep/2026
Agios Pharmaceuticals USD 37.84M 2.09M Sep/2026
Akebia Therapeutics USD 18.7M 5.68M Sep/2026
Alnylam Pharmaceuticals USD 105.91M 8.8M Sep/2026
Anika Therapeutics USD 28.56M 5.73M Jun/2026
Arrowhead Research USD -173.08M 173.08M Dec/2024
AstraZeneca USD 6.93B 362M Jun/2026
Bristol-Myers Squibb USD 2.7B 33M Sep/2026
Eli Lilly USD 18.19B 1.4B Sep/2026
Halozyme Therapeutics USD 132.61M 4.52M Sep/2026
Heron Therapeutics USD 54.57M 2.33M Dec/2022
Insmed USD 163.95M 21.56M Sep/2026
J&J USD 15.38B 233M Sep/2026
Lexicon Pharmaceuticals USD 276K 5K Mar/2026
Ligand Pharmaceuticals USD 14.51M 4.24M Sep/2026
Merck USD 6.16B 43M Sep/2026
Moderna USD 313M 33M Sep/2026
Novartis USD 6.1B 182M Sep/2026
Pfizer USD 10.02B 77M Sep/2026
PTC Therapeutics USD 109.33M 17.98M Sep/2026
Puma Biotechnology USD 9.48M 885K Sep/2025
Sanofi EUR 24.12B 620M Jun/2026
Takeda JPY 1.44T 6.17B Sep/2026
Teva Pharmaceutical Industries USD 3.17B 48M Sep/2026
Ultragenyx Pharmaceutical USD 59M 0 Sep/2026
Vanda Pharmaceuticals USD 1.85M 190K Dec/2025
Veracyte USD 25.82M 3.16M Sep/2026